Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials

doi:10.13105/wjma.v3.i6.254

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15929)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

424

WORD

363

HTML

9274

Figures (1-6)

218

Tables (1-3)

220

Sum=10499

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

524

Download

1586

Sum=2110

Publishing Process of This Article

Item

Count

Browse

1219

Download

2101

Sum=3320

Dec 26, 2015 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Meta-Analysis

ISSN

2308-3840

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Meta-Anal. Dec 26, 2015; 3(6): 254-283
Published online Dec 26, 2015. doi: 10.13105/wjma.v3.i6.254

Full Size Figure Download Figure

Figure 4 Risk of elevated pancreatic enzymes for glucagon-like peptide-1 based agents.

Citation: Shihab HM, Akande T, Armstrong K, Singh S, Loke YK. Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: A systematic review and meta-analysis of randomized trials. World J Meta-Anal 2015; 3(6): 254-283
URL: https://www.wjgnet.com/2308-3840/full/v3/i6/254.htm
DOI: https://dx.doi.org/10.13105/wjma.v3.i6.254